CVP001 is a first-in-class small molecule drug that has been developed to treat ageing-related diseases through improved DNA damage repair. CVP001 targets a novel pathway to increase DNA repair enzyme activity, increasing DNA repair efficiency to prevent the accumulation of DNA damage and subsequently, senescent cells.
CVP001 is being developed for the treatment of osteoporosis and cancer. Its effects on neurodegenerative conditions including Alzheimer’s disease are also being explored in preclinical research.
In developing CVP001 as a first-in-class treatment for age-related diseases such as osteoporosis, cancer and neurodegenerative conditions including Alzheimer’s disease, we aspire to change the lives of those around us and across the globe by improving health outcomes for millions of people affected by these conditions.